Why Conmed (CNMD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Down 16.9% in 4 Weeks, Here's Why Conmed (CNMD) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Conmed (CNMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is CONMED (CNMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Conmed (CNMD) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street Analysts Think Conmed (CNMD) Could Surge 25.54%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Conmed (CNMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Conmed (CNMD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CNMD or MMSI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Conmed (CNMD) or Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?
CONMED Q3 Earnings and Revenues Beat Estimates, Margins Contract
CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction.
CONMED Corporation (CNMD) Q3 2025 Earnings Call Transcript
CONMED Corporation ( CNMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Patrick Beyer - President, CEO & Director Todd Garner - Executive VP of Finance & CFO Conference Call Participants Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Anna Runci - Piper Sandler & Co., Research Division Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Gracia Mahoney - BofA Securities, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Thank you for standing by. Welcome to CONMED's Third Quarter Fiscal 2025 Earnings Conference Call.
Compared to Estimates, Conmed (CNMD) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Tops Q3 Earnings and Revenue Estimates
Conmed (CNMD) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.05 per share a year ago.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD's growth drivers - AirSeal, Buffalo Filter, BioBrace, and Foot & Ankle - are offsetting tariffs and supply risks, making the stock worth retaining.
